Invasive mucormycosis is a life-threatening fungal infection that most frequently occurs in patients with underlying comorbidities that impacts immune system function. It is an opportunistic and frequently fulminant fungal infection caused by a saprophytic organism belonging to class zygomycetes. These organisms are omnipresent and grow in their natural state on the variety of decaying organic materials. These organisms are present in the nasal passages and oral cavities of normal individuals. Here, we report a rare case of juvenile post dengue mucormycosis along with brief insight into the review of literature. Histopathological examination of the necrotic bone and overlying tissue was done in OPD in a juvenile patient who reported with purulent discharge and having a history of dengue. There were abundant PAS positive fungal hyphae. This case report will acquaint the oral care providers of a possible association of mucormycosis and dengue and highlight the importance of early diagnosis to optimize the treatment outcomes and prognosis in such cases. Mucormycosis is a rare opportunistic infection that spreads promptly and is life-threatening. Therefore, early diagnosis and prompt treatment is required to reduce the mortality and morbidity of this lethal infection.

Management of the oral cancer, involves surgical intervention and the associated complications are quite prevalent after oral cancer surgery. This article aims to provide a comprehensive review of all the possible complications associated with surgical management of oral cancer to apprise about adequate management of such complications if they manifest. An internet based literature review was performed in PubMed, Embase and Cochrane Central Register electronic databases using keywords "oral cancer," "oral surgical procedures," "post operative complications," "intra operative complications," which resulted in 19 articles. After screening only relevant English language articles from 2000-2022 were considered. A working classification, described in our study, provides an easier understanding of the possible complications associated with surgical management of the oral cancer. It has been based depending upon their time of occurrence. A learned surgeon thus can provide adequate surgical care and minimize the occurrence of such complications that may occur even with adequate precautions. If such complications do occur, there is always a management protocol.

Owing to high global prevalence, incidence and associated mortality, cancer of head and neck particularly oral cancer remains a cardinal domain for research and trials. Immune-modulatory therapies that employ patients own immune system for therapeutic benefits in oral cancer seems promising. The aim of this review is to gauge the potential of immunotherapy as fourth domain of Oral cancer therapeutics. Articles were searched using suitable search terms in MEDLINE and Google Scholar database to include clinical trials, meta-analyses, and research in humans/animals/cell lines published in peer reviewed journals. A total of 97 articles were included in this review. Literature has several studies and trials where different types of immunotherapies has been attempted but it is crucial to identify precise biomarkers of genome based targeted agents and to find parameters to select patients who might benefit from immunotherapy. Also further research is required to estimate predictive value of tumor mutational burden and mutational signatures so as to aid in personalized prediction of oral cancer therapeutic response.

BACKGROUND:Oral squamous cell carcinoma (OSCC) is a commonly occurring malignancy with complex genetic alterations contributing to its development. The H-Ras, a proto-oncogene, becomes an oncogene when mutated and has been implicated in various cancers. This systematic review aims to research to what extent H-Ras expression and mutation contribute to the development and progression of OSCC, and how does this molecular alteration impacts the clinical characteristics and prognosis in patients with OSCC.METHODS:A thorough electronic scientific literature search was carried out in PUBMED, SCOPUS, and GOOGLE SCHOLAR databases from 2007 to 2021. The search strategy yielded 120 articles. Following aggregation and filtering all results through our inclusion and exclusion criteria total 9 articles were included in our literature review. It has also been registered with PROSPERO (CRD42023485202).RESULTS:It was found that mutations in the Ras gene commonly reported in hotspots at codons 12, 13, and 61 resulting in the activation of downstream signaling pathways causing abnormal and uncontrolled cell growth. This systematic review has shown an increased prevalence of H-Ras mutation in well-differentiated OSCC and also the prevalence of H-Ras mutation in individuals engaging in multiple risk behaviors, particularly chewing tobacco, demonstrated a significant association with a higher prevalence of H-Ras positivity.CONCLUSION:This review sheds light on the prevalence of H-Ras mutations, their association with clinical characteristics, and their potential implications for OSCC prognosis. It also enhances our comprehension of the molecular mechanisms that underlie OSCC and paves the way for further research into targeted treatments based on H-Ras alterations.

Persistent innovation and technological advancements have popularized personalized devices in healthcare that are designed/ manufactured to meet the unique needs of individual patients. However, this rapid growth has raised concerns about the safety and quality of these devices entailing suitable and adaptable regulatory requirements. Although most countries across the globe have either implemented or are in process of doing so in near future, India still lags behind and the existing lacunae needs to be identified for enabling the medical device ecosystem to be in harmony with other countries. In this article, we aim to discuss the current state of the customized implant industry in India and the key lessons that can be learned directing towards opportunities for change to ensure its sustainable growth and development. Literature search in PubMed and Google Scholar following PRISMA guidelines using relevant search terms ‘medical device’ AND ‘regulation’ AND ‘Personalized Medical Devices’ AND ‘Custom made Devices’ OR ‘regulatory bodies’ yielded 36 articles. Only english language articles in journals and relevant data from authentic government portals available online was considered. The diverse regulatory framework across globe is witnessing persistent amendments since two decades. Accelerated use of personalized devices necessitates a proper streamlined regulatory framework providing clear definition and categorization of personalized device possessing single window clearance system, cost transparency, accredited laboratories, use of device identification systems, adequate post insertion record/ feedback database maintenance alongwith trained/ skilled workforce being assessed routinely.

Background & aim: Dendritic cell (DC)-based immunotherapy modulates a patient's immune system for recognition and subsequent removal of tumor cells. DC-mediated anticancer therapy has been considered in several studies/ongoing trials for multiple types of cancer. Our aim is to describe the potential and current status of DC-based immunotherapy in oral cancer therapeutics. Materials & methods: An internet-based literature search with relevant search terms from 2012 to 2022 post-screening resulted in 58 articles that were considered for systematic review. Results & conclusion: Evaluation of DC based immunotherapy exploiting the critical immune cells in well-equipped laboratories with adequately trained and skilled experts along with a synergistic approach that is affordable and approachable to the patients can prove as an efficient anticancer therapy.

Identification of an individual is essential both for legal and humanitarian purposes. Gender identification is an essential criterion required to establish the identity of an individual. The use of molecular techniques in forensic odontology is an emerging field that widens the avenue even in challenging cases of identification. Gender determination using molecular techniques in forensic odontology shows prodigious outcomes and hence befits a frontier in forensic odontology. Identification of an individual in mass disaster and crime investigation cases in the current scenario is an arduous but highly desirable task. Thorough knowledge of forensic genetics is essential and is the need of the hour. Recent advancements in molecular techniques for DNA typing useful in gender determination are both economical and time-saving. These advancements will bring justice to people and large benefits to the society. An exhaustive internet-based literature search was carried out in PubMed and Google Scholar databases using terms ‘gender identification’ OR ‘individual identification’ AND ‘DNA fingerprinting’. The search yielded 1,848 articles. Inclusion criteria included relevance to the context determined by reading the abstract and availability of the full text. A total of 169 articles were selected. After reading the full texts, only articles pertaining to the oral cavity along with relevant articles from the references of the selected articles were considered. A total of 90 articles were considered in the final review. The current article aims to comprehensively review the gender determination molecular techniques useful in forensic odontology. It emphasizes the various sources, techniques, profiling systems, and genes employed for gender identification from the oral cavity.

Backgound and objective: Early chemoprevention in Oral Potentially Malignant Disorders (OPMDs) and Oral Cancer (OC) has been extensively researched in order to mitigate the malignant transformation and progression of the lesion. Many agents have been attempted, but their cost inefficacy and inadequate outcomes posed a major hindrance in their successful adoption. Retinoid Based Therapy (RBT) though a cheap and effective treatment option, could not achieve much clinical usage because of variable responsiveness in clinical outcomes. Such clinical response variability may be attributed to the repression of retinoid receptors by Preferentially Expressed Antigen of Melanoma (PRAME) protein molecule. Therefore, in order to make RBT successful, targeting PRAME by various immunotherapies is an exciting area of research investigation. This review provides an insight into the various immunotherapeutic strategies targeting PRAME and their usefulness in retinoid-resistant OPMD and OC. Method of data collection: An exhaustive internet-based literature search following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines was carried out in PUBMED and Google SCHOLAR database using terms 'Anti-PRAME' OR 'PRAME Immunotherapy' OR 'PRAME Vaccines' AND 'Cancer' AND 'Retinoid resistance'. Only articles in the English language with at least 1 citation, published in a journal with impact factor ≥ 1, having relevance to the context and availability of full text were considered. Results: After an initial search, 342 articles were yielded on the basis of inclusion criteria and, by reading the abstract and availability of full text, a total of 124 articles were selected. Further reading the full texts and considering articles from the references of the selected articles, a total of 65 articles were finally included in the review. Conclusion: Our analysis of the literature suggests that PRAME screening in OC and OPMDs prior to RBT should be done. In PRAME positive cases, approaches like PRAME based immunotherapy in the form of Cancer vaccine therapy [Acellular PRAME vaccine, PRAME pulsed Dendritic Cells (DC)]; Adoptive T Cell therapy/T Cell Receptor-T Cell therapy, Antibody therapy/Chimeric Antigen Receptor-T Cell therapy along with Presented antigen modulation Therapies employing histone deacetylase inhibitors and demethylation agents seem plausible. In the future, a combination therapy employing either PRAME vaccines or antibodies or Adoptive T cell Therapy and ATRA could be used in retinoid resistant OC and OPMDs.

Sudden spurting of Corona virus disease (COVID-19) has put the whole healthcare system on high alert. Internet of Medical Things (IoMT) has eased the situation to a great extent, also COVID-19 has motivated scientists to make new 'Smart' healthcare system focusing towards early diagnosis, prevention of spread, education and treatment and facilitate living in the new normal. This review aims to identify the role of IoMT applications in improving healthcare system and to analyze the status of research demonstrating effectiveness of IoMT benefits to the patient and healthcare system along with a brief insight into technologies supplementing IoMT and challenges faced in developing a smart healthcare system. An internet-based search in PUBMED, Google Scholar and IEEE Library for english language publications using relevant terms resulted in 987 articles. After screening title, abstract, and content related to IoMT in healthcare and excluding duplicate articles, 135 articles published in journal with impact factor ≥1 were eligible for inclusion. Also relevant articles from the references of the selected articles were considered. The habituation of IoMT and related technology has resolved several difficulties using remote monitoring, telemedicine, robotics, sensors etc. However mass adoption seems challenging due to factors like privacy and security of data, management of large amount of data, scalability and upgradation etc. Although ample knowledge has been compiled and exchanged, this structured systematic review will help the healthcare practitioners, policymakers/decision makers, scientists and researchers to gauge the applicability of IoMT in healthcare more efficiently.

INTRODUCTION:This review aims at describing different types of hydrogels in context to their composition, fabrication techniques and other specific features along with an insight into the latest advancements including smart hydrogels, 3D printed, programmable, shape memory and self-healing hydrogels for their applicability as scaffold in maxillofacial bone and cartilage tissue regeneration.METHODS:Electronic database searches were undertaken on PubMed, Ovid, Medline, Embase, ProQuest and science direct for English language literature, published for application of hydrogels in maxillofacial bone and cartilage tissue engineering. The search items used in this article were hydrogel, bone and cartilage tissue engineering, maxillofacial, clinical trials. Reviews and in vitro studies were excluded.RESULTS:Search for injectable hydrogel showed 4955 articles, when restricted to bone tissue engineering results were reduced to 463 and for cartilage engineering to 335; when we limited it to maxillofacial bone and cartilage tissue engineering, search results showed 49 articles to which 9 additional articles were included from references, after exclusion of in-vitro studies and duplicates 16 articles were obtained for our study. Similarly, for 3D printed hydrogels, result showed 1126 articles, which got restricted to 19 when searched for maxillofacial bone and cartilage engineering, then 2 additional articles were included directly from references, and finally after exclusion of the invitro studies and duplicates, a total of 5 articles were obtained.CONCLUSION:Modifications in hydrogel can improve the mechanical properties, biocompatibility and unique chemistries for its use in bone and cartilage tissue engineering for future research.

Oral cancers needs relentless research due to high mortality and morbidity associated with it. Despite of the comparable ease in accessibility to these sites, more than 2/3rd cases are diagnosed in advanced stages. Molecular/genetic studies augment clinical assessment, classification and prediction of malignant potential of oral lesions, thereby reducing its incidence and increasing the scope for early diagnosis and treatment of oral cancers. Herein we aim to review the role of apoptosis and genes associated with it in oral cancer development in order to aid in early diagnosis, prediction of malignant potential and evaluation of possible treatment targets in oral cancer. An internet-based search was done with key words apoptosis, genes, mutations, targets and analysis to extract 72 articles after considering inclusion and exclusion criteria. The knowledge of genetics and genomics of oral cancer is of utmost need in order to stop the rising prevalence of oral cancer. Translational approach and interventions at the early stage of oral cancer, targeted destruction of cancerous cells by silencing or promoting involved genes should be the ideal intervention.

Polyhydroxyalkanoates (PHA) are prokaryotic macromolecules accumulated within the cytoplasm as granules. Due to their suitable mechanical properties, biocompatibility, degradation time, ability to be blended, surface modified, and form copolymers, it is widely used in medical devices and as scaffolds in bone tissue engineering. This review describes in brief the production and extraction sources, physico-chemical characteristic, mechanical properties, degradation rate and applications of various PHAs and its copolymers with special emphasis to its role as scaffolds in bone tissue engineering.

Dental Stem cells are undifferentiated cells isolated from tooth and associated structures. Dental stem cells can be easily obtained from both adult and deciduous teeth, the periodontal ligament, the apical papilla and the dental follicle. Their subsequent differentiation can be utilized to replace the lost tooth structures. Here we aim to highlight potential of dental stem cells from varied origin for tooth regeneration. Several studies have demonstrated tooth tissue regeneration. Application of recent 3D bioprinting technology has further enhanced probability of accurate tooth tissue regeneration. However complete tooth regeneration is still a future thing.

Bcl-2 (B cell Lymphoma −2) family comprises of both anti-apoptotic and pro-apoptotic proteins whose altered expression or change in ratio inhibits apoptosis, and promotes tumor progression. The aim of this study is to assess the usefulness of Bcl-2 in distinguishing dysplastic or malignant epithelium from non-dysplastic or normal epithelium to aid in prediction of malignant transformation potential.Material and methodStudy group comprised of 30 cases of clinically diagnosed leukoplakia (OPMD), 15 cases of Oral Squamous Cell Carcinoma (OSCC) and 5 normal tissue samples. The labeling index of Bcl-2 was analyzed in immunohistochemically stained sections. Different statistical tools were used to analyze the data and to compare Bcl-2 expression qualitatively and quantitatively among all the groups.ResultsAn increasing trend of Bcl-2 immunoexpression was observed from normal epithelium to non-dysplastic and from non-dysplastic to dysplastic lesions. In OSCC, the peripheral cells in the differentiating epithelial islands (within the connective tissue) showed Bcl-2 immuno-reactivity, which gradually decreased towards the center. In contrast, intense and diffuse Bcl-2 immuno-reactivity was seen in poorly differentiated carcinoma. But the overall Bcl-2 positivity was less in OSCC as compared to dysplastic lesions.ConclusionIncreased expression of Bcl-2 oncoprotein in sequentially progressing epithelial dysplasia and down-regulation in differentiating carcinoma (well and moderately differentiating OSCC) unveils the clinical relevance of Bcl-2 in early stages of OSCC tumorigenesis. The heterogenous expression of Bcl-2 in carcinoma with different grades of differentiation renders them unable to be used as an independent tool for predicting transition from oral pre-malignancy to malignancy.

Bone tissue engineering using polymer based scaffolds have been studied a lot in last decades. Considering the qualities of all the polymers desired to be used as scaffolds, Polycaprolactone (PCL) polyester apart from being biocompatible and biodegradable qualifies to an appreciable level due its easy availability, cost efficacy and suitability for modification. Its adjustable physio-chemical state, biological properties and mechanical strength renders it to withstand physical, chemical and mechanical, insults without significant loss of its properties. This review aims to critically analyse the efficacy of PCL as a biomaterial for bone scaffolds.

BackgroundConsidering the structural and functional complexity of the craniofacial tissues, 3D bioprinting can be a valuable tool to design and create functional 3D tissues or organs in situ for in vivo applications. This review aims to explore the various aspects of this emerging 3D bioprinting technology and its application in the craniofacial bone or cartilage regeneration.MethodElectronic database searches were undertaken on pubmed, google scholar, medline, embase, and science direct for english language literature, published for 3D bioprinting in craniofacial regeneration. The search items used were ‘craniofacial regeneration’ OR 'jaw regeneration' OR 'maxillofacial regeneration' AND ‘3D bioprinting’ OR 'three dimensional bioprinting' OR 'Additive manufacturing' OR 'rapid prototyping' OR 'patient specific bioprinting'. Reviews and duplicates were excluded.ResultsSearch with above described criteria yielded 476 articles, which reduced to 108 after excluding reviews. Further screening of individual articles led to 77 articles to which 9 additional articles were included from references, and 18 duplicate articles were excluded. Finally we were left with 68 articles to be included in the review.ConclusionCraniofacial tissue and organ regeneration has been reported a success using bioink with different biomaterial and incorporated stem cells in 3D bioprinters. Though several attempts have been made to fabricate craniofacial bone and cartilage, the strive to achieve desired outcome still continues.

High morbidity and mortality associated with oral cancers and its high incidence and prevalence necessitates earlier diagnosis and effective management. Despite of ease in morphological accessibility, oral cancers are still diagnosed mostly in advanced stages chiefly due to lack of effective and cheap screening tools.The search of a suitable biomarker, which can diagnose, oral cancer effectively and can predict the progression of Oral Potentially malignant Disorders (OMPD) to Oral Cancer with accuracy, still exists. PRAME (Preferentially Expressed Antigen of Melanoma) is one such biomarker, which is a dominant repressor of Vitamin A (Vit A). Vit A, chiefly Retinoic Acid (RA) is extensively used these days for chemoprevention owing to its role in cell growth and differentiation. RA emerged as a cheap and acceptable chemo preventive agent since RA is readily available in the form of Vit A food supplements, Vit A is being used in patients with various grades of OPMDs and oral cancer, but its efficiency is still debatable owing to its mixed results in various cancers. Inconsistency in efficient results led to study of various molecules like PRAME, which is involved in RA metabolic pathway thereby modulating the outcome and efficacy of Retinoic Acid chemoprevention. *Correspondence to: Rahul Pandey, Scientist, DHR-MRU,King George Medical University, Lucknow226003, U.P, India, Tel: 9889175042; E-mail: pandey.rahul.dr@gmail.com

INTRODUCTION:One of the common findings encountered by the clinician at the end of orthodontic treatment is the apical root resorption. Root resorption occurs to various degrees. A severe form of root resorption is characterized by shortening of root for more than 4 mm or more than one-third of the total tooth length. A low incidence rate of resorption is observed based on radiographic findings for the diagnosis of root resorption, panoramic radiography, and periapical radiography. Hence, we evaluated the accuracy of panoramic radiographic films for assessing the root resorption in comparison with the periapical films.MATERIALS AND METHODS:This study included the assessment of all the cases in which pre- and post-treatment radiographs were available for analysis of the assessment of the amount of root resorption. Complete records of 80 patients were analyzed. Examination of a total of 900 teeth was done. Mean age of the patients in this study was 21 years ranging from 11 to 38 years. The majority of the patients in the present study were females. All the treatments were carried out by registered experienced orthodontists having minimum experience of more than 10 years. All the cases were divided into two study groups. Group I comprised panoramic radiographic findings, while group II consisted of periapical radiographic findings. For the measurement of crown portion, root portion, and the complete root length, magnification loops of over 100 powers with parallax correction with inbuilt grids were used. Assessment of the tooth length and the crown length was done by the same observers. All the results were analyzed by Statistical Package for the Social Sciences software version 6.0.RESULTS:Maximum amount of root resorption was observed in case of maxillary central incisors and canines among group I and II cases respectively. However, nonsignificant difference was obtained while comparing the mean root resorption in relation to maxillary incisors and canines among the two study groups. While comparing the overall value of root resorption among the two study groups, a significant difference was obtained. The maximum value of tooth length in both the groups was observed in cases of maxillary canines. Significant differences were observed while comparing the tooth length of various teeth among the two study groups. Among the deviated forms of root shape, dilacera-tion was the most common form of root shape detected in both the study groups.CONCLUSION:Periapical radiographs are more efficient in the assessment of the shape and resorption of the root.CLINICAL SIGNIFICANCE:Thorough evaluation of periapical radiographs is necessary for detection of even minute levels of root resorption.

South Asian Journal of Cancer ♦ October-December 2016 ♦ Volume 5♦ Issue 4 191 9. Maskarinec G, Pagano I, Lurie G, Bantum E, Gotay CC, Issell BF. Factors affecting survival among women with breast cancer in Hawaii. J Womens Health (Larchmt) 2011;20:231–7. 10. Brooks JD, John EM, Mellemkjær L, Reiner AS, Malone KE, Lynch CF, et al. Body mass index and risk of second primary breast cancer: The WECARE Study. Breast Cancer Res Treat 2012;131:571–80. 11. De Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA. The metabolic Syndrome in cancer survivors. Lancet Oncol 2010;11:193–203. 12. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer 2008;44:293–7. 13. Elder JP. Mexico and the USA: The world’s leaders in the obesity epidemic. Salud Publica Mex 2013;55 Suppl 3:355. 14. Cárdenas-Sánchez J, Erazo-Valle A, Maafs E, Poitevin A. National consensus on diagnosis and treatment of breast cancer. Fourth revision. Colima, Mexico. GAMO 2011;10:1–58. 15. Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study. Nutr Metab Cardiovasc Dis 2010;20:41–8. 16. Bjørge T, Lukanova A, Jonsson H, Tretli S, Ulmer H, Manjer J, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010;19:1737–45. 17. Capasso I, Esposito E, Pentimalli F, Crispo A, Montella M, Grimaldi M, et al. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol Ther 2010;10:1240–3. 18. Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V, Boyle T, et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 2010;22:281–8. 19. Porto LA, Lora KJ, Soares JC, Costa LO. Metabolic syndrome is an independent risk factor for breast cancer. Arch Gynecol Obstet 2011;284:1271–6. 20. Osaki Y, Taniguchi S, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol 2012;36:141–7. 21. Bjørge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 2010;171:892–902. 22. Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol 2011;22:884–9. 23. Friedenreich CM, Biel RK, Lau DC, Csizmadi I, Courneya KS, Magliocco AM, et al. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2384–95. 24. Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): Analysis of six prospective cohorts. PLoS Med 2009;6:E1000201. 25. Häggström C, Rapp K, Stocks T, Manjer J, Bjørge T, Ulmer H, et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One 2013;8:E57475. 26. Oh SW, Park CY, Lee ES, Yoon YS, Lee ES, Park SS, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: A cohort study. Breast Cancer Res 2011;13:R34. 27. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009;15:5141–8. 28. Goodwin PJ, Ennis M, Bahl M, Fantus IG, Pritchard KI, Trudeau ME, et al. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 2009;114:517–25. 29. Sánchez L, Lana A, Hidalgo A, Rodríguez JM, Del Valle M del O, Cueto A, et al. Risk factors for second primary tumours in breast cancer survivors. Eur J Cancer Prev 2008;17:406–13. 30. Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjørge T, et al. Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control 2011;22:291–9. 31. Ortiz-Mendoza CM, Velasco-Navarro C. Obesity, a main risk factor for endometrial cancer. Rev Med Inst Mex Seguro Soc 2013;51:260–3. 32. Glance LG, Wissler R, Mukamel DB, Li Y, Diachun CA, Salloum R, et al. Perioperative outcomes among patients with the modified metabolic syndrome who are undergoing noncardiac surgery. Anesthesiology 2010;113:859–72. 33. Mehdi I, Shah AH, Moona MS, Verma K, Abussa A, Elramih R, et al. Synchronous and metachronous malignant tumours expect the unexpected. J Pak Med Assoc 2010;60:905–9. 34. Vidal-Millan S, Zeichner-Gancz I, Flores-Estrada D, Vela-Rodríguez BE, Vazquez-López MI, Robles-Vidal CD, et al. A descriptive study of second primary malignancies associated to breast cancer in a mexican Hispanic population. Med Oncol 2005;22:17–22. 35. Lee KD, Chen SC, Chan CH, Lu CH, Chen CC, Lin JT, et al. Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: A population-based study in Taiwan. Cancer Epidemiol Biomarkers Prev 2008;17:2647–55. 36. Lana Pérez A, Folgueras Sánchez MV, Díaz Rodríguez S, del Olivo del Valle Gómez M, Cueto Espinar A, López González ML. Survival analysis in multiple cancer patients in Asturias, Spain, 1975–2004. Rev Esp Salud Publica 2008;82:167–77. 37. Grunfeld E, Moineddin R, Gunraj N, Del Giudice ME, Hodgson DC, Kwon JS, et al. Cancer screening practices of cancer survivors: Population-based, longitudinal study. Can Fam Physician 2012;58:980–6.